A Retrospective analysis of isoniazid-monoresistant tuberculosis: Among Iranian pulmonary tuberculosis patients

Open Microbiology Journal

Volumn 8, Issue 1, 2014, Pages 1-5

  Varahram, Mohammad ^a   Nasiri, Mohammad Javad ^a   Farnia, Parissa ^a   Mozafari, Mohadese ^a   Velayati, Ali Akbar ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Drug resistance; Iran; Isoniazid; Mycobacterium tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ADULT; AGE; ARTICLE; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVITY; FEMALE; HUMAN; IRANIAN PEOPLE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 84899802667     PISSN: None     EISSN: 18742858     Source Type: Journal    
DOI: 10.2174/1874285801408010001     Document Type: Article

References (22)

1. World Health Organization (WHO). Global Health Observatory Data Repository. 2 013. avolable from: http://appswho int/ghodata 2013.
2. Masjedi MR, Farnia P, Sorooch S, et al. Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran. Clin Infect Dis 2006; 43: 841-7.
3. Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacillisuper extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest J 2009; 136: 420-5.
4. Velayati AA, Farnia P, Masjedi MR. Totally drug-resistant tuberculosis (TDR-TB): A debate on global health communities. Int J Mycobacteriol 2013.
5. Velayati AA, Farnia P, Masjedi MR. Letter to Editor The totally drug resistant tuberculosis (TDR-TB). Int J Clin Exp Med 2013; 6: 307-09.
6. Wright A, Zignol M, Van Deun A, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the global project on anti-tuberculosis drug resistance surveillance. Lancet 2009; 373: 1861-73.
7. Rieder HL. Interventions for tuberculosis control and elimination: international union against tuberculosis and lung disease paris 2002.
8. Falzon D, Jaramillo E, Schünemann H, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-28.
9. Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009; 6: e1000150.
10. Petroff S. A new and rapid method for the isolation and cultivation of tubercle bacilli directly from the sputum and feces. J Exp Med 1915; 21: 38-42.
11. Kamerbeek J, Schouls L, Kolk A, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997; 35: 907-14.
12. Dvorska L, Bartos M, Martin G, Erler W, Pavlik I. Strategies for differentiation, identification and typing of medically important species of mycobacteria by molecular methods. Vet Med-Praha 2001; 46: 309-28.
13. Rieder HL, Chonde TM, Myking H, et al. The public health service national tuberculosis reference laboratory and the national laboratory network; minimum requirements, role and operation in a low-income country. Paris, France: International Union against Tuberculosis and Lung Disease (IUATLD) 1998.
14. Velayati AA, Farnia P, Mozafari M, et al. High prevelance of rifampin-monoresistant Tuberculosis: A retrospective analysis among iranian pulmonary tuberculosis patients. Am J Trop Med Hyg 2014; 90(1): 99-105.
15. World Health Organization (WHO). Global tuberculosis report 2013.
16. Sotgiu G, Centis R, D'Ambrosio L, et al. Do we need a new Fleming époque: The nightmare of drug-resistant tuberculosis. Int J Mycobacteriol 2013; 2: 123-25.
17. Shamaei M, Marjani M, Chitsaz E, et al. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran-eight years of surveillance. Int J Infect Dis 2009; 13: e236-e40.
18. Merza MA, Farnia P, Tabarsi P, et al. Anti-tuberculosis drug resistance and associated risk factors in a tertiary level TB center in Iran: a retrospective analysis. J Infect Dev Ctries 2011; 5: 511-19.
19. Dispensary AT, Street I. Drug-resistant pulmonary tuberculosis in western Turkey: prevalence, clinical characteristics and treatment outcome. Ann Saudi Med 2005; 25: 313-18.
20. Hoopes AJ, Kammerer JS, Harrington TA, Ijaz K, Armstrong LR. Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003. Arch Intern Med 2008; 168: 1984.
21. Forssbohm M, Loddenkemper R, Rieder H. Isoniazid resistance among tuberculosis patients by birth cohort in Germany. Int J Tuberc Lung Dis 2003; 7: 973-9.
22. Hasan R, Jabeen K, Mehraj V, et al. Trends in Mycobacterium tuberculosis resistance, Pakistan, 1990-2007. Int J Infect Dis 2009; 13: e377-e82.